Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[64Cu]NOTA-TVS-W-PSMA dimer
- Development stage
- Preclinical
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[64Cu]NOTA-TVS-W-PSMA dimer is a dimeric, prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical developed by the University of North Carolina at Chapel Hill and licensed to Tripill Biotech. Built upon a tri-vinyl sulfone (TVS) scaffold, the agent incorporates a tunable tryptophan (W) amino acid linker between the PSMA-targeting ligand and the vinyl sulfone moiety to optimize pharmacokinetics. Radiolabeled with copper-64 (64Cu), this dimeric PET tracer is designed for the diagnostic imaging of PSMA-positive prostate cancer. In preclinical studies, the tryptophan linker significantly reduced off-target kidney and salivary gland uptake while maintaining high tumor retention and specificity, addressing the renal and glandular toxicities associated with conventional monomeric PSMA-targeted agents.
- Other names
- [64Cu]-NOTA-TVS-W-PSMA dimer[64Cu]NOTA-TVS-W-PSMA dimer
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on [64Cu]NOTA-TVS-W-PSMA dimer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [64Cu]NOTA-TVS-W-PSMA dimer.